<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04304768</url>
  </required_header>
  <id_info>
    <org_study_id>20200178</org_study_id>
    <nct_id>NCT04304768</nct_id>
  </id_info>
  <brief_title>Opioid, HIV and Immune System</brief_title>
  <official_title>Immune Dysfunction in HIV+ Opioid Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate blood samples from HIV infected and non-HIV
      infected people opioid and non opioid users to understand how opioid affect the immune
      responses (body defenses against infection) to the flu vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the antibody response</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>Antibody response as measured by the serum vaccine antigen specific hemagglutination inhibition antibody levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune activation levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Activation of T and B cells from peripheral blood mononuclear cells assessed via flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation biomarker levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Plasma levels of Interleukin (IL)-6, IL-8, IL-12, IL-17, IL-22, Tumor necrosis factor (TNF) and monocyte activation markers soluble CD14 and soluble CD163 will be assessed via Magpix. All the biomarkers will be measured in nanograms/milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating T follicular helper cell function</measure>
    <time_frame>Week 4</time_frame>
    <description>T follicular helper cell function measured from peripheral blood mononuclear cells via flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating T follicular helper cell frequency</measure>
    <time_frame>Week 4</time_frame>
    <description>T follicular helper cell frequency measured from peripheral blood mononuclear cells via flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Immune Defect</condition>
  <arm_group>
    <arm_group_label>HIV positive opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV positive non-opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will continue their standard of care antiretroviral therapy (ART) and receive flu vaccination as part of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive flu vaccination as part of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative non-opioid users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive flu vaccination as part of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Quadrivalent</intervention_name>
    <description>0.5 ml prefilled syringe administrated intramuscularly</description>
    <arm_group_label>HIV negative non-opioid users</arm_group_label>
    <arm_group_label>HIV negative opioid users</arm_group_label>
    <arm_group_label>HIV positive non-opioid users</arm_group_label>
    <arm_group_label>HIV positive opioid users</arm_group_label>
    <other_name>Influenza vaccination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For Opioid (OP) users/non-users:

          1. OP users - prescribed opioids for at least the past 90 days; or injecting opioids for
             at least 90 days

          2. Opioid never-users in the past year

        Additional criteria for OP users:

          1. OP use for 90 days pre-flu vaccination

          2. Continued OP use for 4 weeks post flu vaccination

        For HIV positive participants:

        1) HIV infection, as documented by any licensed ELISA kit and confirmed by Western blot at
        any time prior to study entry. Participants on ART as a result of prior HIV documented
        infection will not be required to provide proof of diagnosis of HIV infection.

        Additional criteria for HIV positive participants:

          1. On ART for at least 1 year with plasma pending viral load (VL) &lt;50 copies/mL.
             Occasional viral blips up to 1000 copies/ml also acceptable provided the patients are
             on continuing treatment

          2. CD4 count available in the prior 6 months and &gt;200/mm3

          3. Undetectable viral load (&lt; 40 copies/mL)

        For HIV negative participants:

        1) Documented negative HIV test, either by any licensed ELISA or rapid tests within the
        past 6 months.

        For all participants:

          1. Individuals age &gt;18-60 yrs .

          2. No history of other immunodeficiency disorders

          3. Not on steroid or other immunosuppressive/immunomodulators medications.

          4. No active malignancies.

          5. No contraindication to receive influenza vaccination (allergy to chicken eggs or to
             any other substance of the vaccine).

          6. Agreeable to receive the influenza vaccination.

          7. Agreeable to participate in study for a complete course of study full visits.

          8. Able to provide informed consent.

        Exclusion Criteria:

          1. Contraindication to receive influenza vaccination (allergy to chicken eggs or to any
             other substance of the vaccine).

          2. Non-adherence to ART for HIV+

          3. Unable to provide informed consent.

          4. Other comorbid conditions such as diabetes mellitus type 2 (DMT2)

          5. Influenza vaccination already given during the current vaccination season.

          6. Polydrug abuse including cocaine by history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Savita Pahwa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Savita Pahwa, MD</last_name>
    <phone>3052437732</phone>
    <email>spahwa@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suresh Pallikkuth, PhD</last_name>
    <phone>3052435315</phone>
    <email>SPallikkuth@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Savita Pahwa, MD</last_name>
      <phone>305-243-7732</phone>
      <email>spahwa@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Suresh Pallikkuth, PhD</last_name>
      <phone>3052435315</phone>
      <email>SPallikkuth@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Savita Pahwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Savita Pahwa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Flu vaccine response and HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

